Moleculin Biotech, Inc. (MBRX)
0.77
+0.02
(+2.65%)
USD |
NASDAQ |
Sep 09, 15:06
Moleculin Biotech Shareholders Equity (Quarterly) : 11.59M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.59M |
| March 31, 2026 | 15.18M |
| December 31, 2025 | 15.01M |
| September 30, 2025 | -26.92M |
| June 30, 2025 | -7.165M |
| March 31, 2025 | 0.042M |
| December 31, 2024 | 11.21M |
| September 30, 2024 | 11.21M |
| June 30, 2024 | 17.70M |
| March 31, 2024 | 21.59M |
| December 31, 2023 | 26.07M |
| September 30, 2023 | 35.14M |
| June 30, 2023 | 40.27M |
| March 31, 2023 | 45.68M |
| December 31, 2022 | 52.19M |
| September 30, 2022 | 58.42M |
| June 30, 2022 | 66.36M |
| March 31, 2022 | 72.66M |
| December 31, 2021 | 78.99M |
| September 30, 2021 | 81.26M |
| June 30, 2021 | 84.71M |
| March 31, 2021 | 88.52M |
| Date | Value |
|---|---|
| December 31, 2020 | 17.89M |
| September 30, 2020 | 14.47M |
| June 30, 2020 | 15.63M |
| March 31, 2020 | 15.29M |
| December 31, 2019 | 15.57M |
| September 30, 2019 | 18.98M |
| June 30, 2019 | 22.09M |
| March 31, 2019 | 14.68M |
| December 31, 2018 | 14.27M |
| September 30, 2018 | 14.97M |
| June 30, 2018 | 16.75M |
| March 31, 2018 | 20.57M |
| December 31, 2017 | 17.12M |
| September 30, 2017 | 18.65M |
| June 30, 2017 | 19.27M |
| March 31, 2017 | 16.14M |
| December 31, 2016 | 14.96M |
| September 30, 2016 | 16.25M |
| June 30, 2016 | 17.49M |
| March 31, 2016 | -0.6853M |
| December 31, 2015 | -0.7417M |
| September 30, 2015 | -0.2269M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 21.09M |
| Total Liabilities (Quarterly) | 9.50M |
| Debt to Equity Ratio | 0.0252 |
| Current Ratio | 0.9366 |
| Net Debt Paydown Yield | 0.16% |